New Beta Innovation Limited

ABOUT US

New Beta Innovation Canada Limited (NBI-CA) is a biopharmaceutical manufacturer of hemoglobin-based therapeutics. Our production processes are undergoing validation for rigorous Good Manufacturing Practice (GMP) requirements. We have a state-of-the-art facility with custom-designed equipment for commercial-scale production.

Our operations include a full in-house analytical laboratory, a water purification plant, a skilled engineering team, and experts in compliance ...

CORPORATE RESPONSIBILITIES

OUR OPERATIONS

BIOPHARMACEUTICAL MANUFACTURING

NBI-CA’s production department manages and operates our state-of-the-art commercial-scale facility. The manufacturing capacity for sterile liquid biopharmaceuticals in our 45 cleanrooms is one of the largest of its kind in Western Canada. Regulatory approval and Good Manufacturing Practice (GMP) compliance are underway as our team diligently prepares for future commercial production of hemoglobin-based therapeutics.

OUR SCIENCE

RESEARCH & DEVELOPMENT

Our research and clinical development focus on the following therapeutic areas:

View Publications

Oncological Disorder

Neurological Disorder

Ischemic Condition

Oncological Disorder

Neurological Disorder

Ischemic Condition

CLINICAL DEVELOPMENT

Phase l Clinical Trial

Study Title: YQ23 Study in Patients With Critical Limb Ischaemia

This is an early phase study to assess the safety and tolerability of the new study drug YQ23 and to compare the effectiveness of YQ23 against a normal saline control to treat critical limb ischaemia. The study also aims to understand how it affects the body and will assess how the human body takes up, breaks down, and clears the study drug. (Read More)

Study Title: First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23
Completed

This study is to test the safety, tolerability, pharmacokinetics (PK-the amount of study drug in the blood), and immunogenicity (how the study drug affects the immune system) of single dose and dose levels of an investigational drug called YQ23. (Read More)

Study Title: A Safety Study of YQ23 in Advanced Solid Tumors Patients

This is an early phase dose escalation study which is divided into two stages: (1) single agent of the test drug YQ23, and (2) in combination with pembrolizumab administered to patients with advanced solid tumors. The purpose of the study is to establish the safety and tolerability profile, as well as the maximum tolerated dose (MTD) of YQ23 as a single agent (stage 1) and in combination with pembrolizumab (stage 2). Stage 2 will start only when the MTD of single agent YQ23 has been established in Stage 1. (Read More)

NEWS

Summary

27 November, 2019

New Beta Innovation Canada Ltd.’s Facilities Compliant under Health Canada Drug Establishment Regulations

In February of this year, Health Canada auditors completed a rigorous 5-day on-site inspection of New Beta Innovation Canada Limited’s ...

1-2 March, 2018

Event Sponsor: ICPOEP 2018

sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 4th International Conference on Phase 1 and...

3-4 November, 2016

Event Sponsor: ICPOEP 2016

NBI sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 3rd International Conference on Phase 1 ...

11 July, 2016

NBI receives HK DOH approval to proceed with a Phase 1 Clinical Trial (First in Patient) of YQ23 in patients with advanced tumors.

21 March, 2016

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

13 October, 2015

NBI receives UK MHRA approval to proceed with a Phase 1 Clinical Trial (First in human) of YQ23 in healthy volunteers.

19 November, 2014

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

27 November, 2019

New Beta Innovation Canada Ltd.’s Facilities Compliant under Health Canada Drug Establishment Regulations

In February of this year, Health Canada auditors completed a rigorous 5-day on-site inspection of New Beta Innovation Canada Limited’s ...

1-2 March, 2018

Event Sponsor: ICPOEP 2018

sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 4th International Conference on Phase 1 and...

3-4 November, 2016

Event Sponsor: ICPOEP 2016

NBI sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 3rd International Conference on Phase 1 ...

11 July, 2016

NBI receives HK DOH approval to proceed with a Phase 1 Clinical Trial (First in Patient) of YQ23 in patients with advanced tumors.

21 March, 2016

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

13 October, 2015

NBI receives UK MHRA approval to proceed with a Phase 1 Clinical Trial (First in human) of YQ23 in healthy volunteers.

19 November, 2014

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

CAREERS

We believe a dedicated, talented, quality-focused work force is a vital asset to the company and fundamental to our success. We are constantly seeking qualified members who are passionate about doing great work to join our team.

We encourage all interested parties to apply for any of the vacancies listed below. We offer a competitive remuneration package, wide-range of training opportunities and career development prospects. If you are eager to create an exciting and rewarding career, please send us your full resume for consideration.

All personal data collected will be treated in strict confidence and will only be used for recruitment purposes. Please read our privacy policy for further information about how we handle personal data in relation to job applications for vacancies in canada.

COUNTRY